Sevelamer, a Phosphate-Binding Polymer, is a Non-Absorbed Compound

ObjectiveTo examine the absorption, distribution and excretion of sevelamer hydrochloride in rats and humans.ParticipantsTwelve male Sprague-Dawley rats were used in the animal study, and twenty human volunteers participated in the clinical trial.MethodsIn the animal study, six rats received a single oral dose of [3H]sevelamer and six rats were pretreated with unlabelled sevelamer in the diet for 28 days followed by a single dose of [3H] sevelamer on day 29. Total urine and faeces were collected at intervals up to 72 hours post dose, and tissues were obtained at the time of sacrifice. In the clinical trial, subjects received a single oral dose of [14C]sevelamer following 28 days of pretreatment with unlabelled sevelamer. Blood, urine and faeces samples were collected at intervals up to 96 hours.ResultsIn the rat study, no significant urinary excretion of radioactivity was observed. The average recovery of radioactivity in the faeces was 98% in the single-dose group and greater than 100% in the group pretreated with unlabelled sevelamer for 28 days. A total of less than 0.1% of the dose was found in the tissues. In the human study, no detectable amount of 14C was found in the blood of any subject at any time. The majority of subjects had no detectable amounts of 14C recovered in the urine. In subjects where 14C was recovered in the urine, less than 0.02% was detected, a level equivalent to the free 14C detected in the [14C]sevelamer preparation. On average, greater than 99% of the administered dose was recovered in the faeces of the subjects.ConclusionThese studies demonstrate that sevelamer is a non-absorbed compound.

[1]  W. Goodman,et al.  Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. , 1991 .

[2]  E. Slatopolsky,et al.  RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. , 1999, Kidney international.

[3]  A. L. Sheffner,et al.  The Disposition of Orally Administered Cholestyramine-C14 , 1965, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[4]  J. L. Greger,et al.  Excretion and retention of low or moderate levels of aluminium by human subjects. , 1983, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[5]  A. Pierides,et al.  Hemodialysis encephalopathy with osteomalacic fractures and muscle weakness. , 1980, Kidney international.

[6]  F. Malberti,et al.  Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism. , 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  J. Delmez,et al.  Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. , 1986, The New England journal of medicine.

[8]  B. Garrett,et al.  A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  Burke,et al.  Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  A. Alfrey Aluminum Toxicity in Patients with Chronic Renal Failure , 1993, Therapeutic drug monitoring.

[11]  L. Allen Calcium bioavailability and absorption: a review. , 1982, The American journal of clinical nutrition.

[12]  C. Hsu,et al.  Are we mismanaging calcium and phosphate metabolism in renal failure? , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  T. Feest,et al.  FRACTURING DIALYSIS OSTEODYSTROPHY AND DIALYSIS ENCEPHALOPATHY An Epidemiological Survey , 1979, The Lancet.

[14]  B. Garrett,et al.  A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. , 1999, Clinical nephrology.

[15]  I. Huq,et al.  Letters to the EditorAMPICILLIN-RESISTANT SHIGA BACILLUS IN BANGLADESH , 1974 .